3M Drug Delivery Systems recently entered a new phase of its collaboration with Panacea Pharmaceuticals Inc. to deliver an investigational therapeutic cancer vaccine.
In Phase 1 of the clinical study, a patient was given Panacea Pharmaceuticals' vaccine, which is an achievement for both companies.
The vaccine is delivered to the dermis with a hollow microstructured transdermal system (hMTS).
“Our hollow microneedles bring a new value proposition to their work with therapeutic cancer vaccines – offering the convenience of a transdermal patch paired with a coveted high-volume, reproducible delivery capability to the dermis," Silvia Perez, president and general manager of 3M Drug Delivery Systems, said in a press release from Panacea Pharmaceuticals.
Pre-clinical studies have shown that patients may have a better immune response with the hMTS compared to intramuscular dosing, Steve Fuller, Panacea Pharmaceuticals's chief operating officer, said in the release.
“Because we need to deliver a 1 mL volume of our vaccine to the dermis, 3M’s hMTS is the delivery method of choice for our therapeutic cancer vaccine project moving forward,” Fuller said.
The benefits of the
hMTS include the ability to deliver up to 2 mL in various viscosities.
3M Drug Delivery partners with Panacea Pharmaceuticals on cancer vaccine